{"description":"Toxicity was graded and recorded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE grading table)","eventGroups":[{"description":"Bevacizumab: Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3","id":"EG000","otherNumAffected":0,"otherNumAtRisk":7,"seriousNumAffected":0,"seriousNumAtRisk":7,"title":"HAART"},{"description":"Bevacizumab: Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3","id":"EG001","otherNumAffected":0,"otherNumAtRisk":7,"seriousNumAffected":1,"seriousNumAtRisk":7,"title":"HAART+ Bevacizumab Injection"}],"frequencyThreshold":"5","seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"A patient had fever of 39°C after 3 days of receiving the first BVZ injection and starting ART. He was hospitalized and bronchoscopy revealed Mycobacterium avium complex pulmonary disease, so he was treated with clarithromycin and ethambutol.","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"DAIDS AE","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":7,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":7,"numEvents":1}],"term":"Fever"}],"timeFrame":"1 year"}